AstraZeneca and Merck in Global Oncology Pact

05:45 EDT 1 Aug 2017 | CHEManager

AstraZeneca has entered into a global collaboration with US drugmaker Merck to develop and commercialize the former’s investigational cancer treatments Lynparza (olaparib) and selumetinib. Lynparza is a first-in-class oral poly ADP ribose polymerase (PARP) inhibitor that is approved for BRCA-mutated ovarian cancer in multiple lines of treatment. The therapy has 14 indications currently being developed across several tumor types, including breast, prostate and pancreatic tumors.

Original Article: AstraZeneca and Merck in Global Oncology Pact


More From BioPortfolio on "AstraZeneca and Merck in Global Oncology Pact"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...